Detalhe da pesquisa
1.
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Nature;
595(7867): 432-437, 2021 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34135506
2.
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol;
22(4): 525-537, 2021 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33721560
3.
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
Eur Urol;
85(2): 114-122, 2024 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37500339
4.
Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumors.
PLoS One;
19(5): e0302129, 2024.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38753705
5.
Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay.
Front Oncol;
13: 1221718, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37601688
6.
"Real-world" outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma.
Urol Oncol;
39(1): 76.e15-76.e22, 2021 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32778476
7.
Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma.
Oncoimmunology;
9(1): 1824645, 2020 10 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33101774